5 terminated. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 5 |
| Phase 2 | 4 | Terminated 4 |
Follow Hearing Loss: new trials by email Literature Review of Hearing Loss trials Research Report on Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss FX-345, Placebo - Hearing Loss, Sensorineural | Phase 1 | Terminated | Frequency Therapeutics | 6 | 2022-12-15 | 2023-04-27 |
| Efficacy of Platelet Enriched Plasma in Preventing Surgery for Patients With Chronic Tympanic Membrane Perforation Platelet Rich Plasma - Tympanic Membrane Perforation | Phase 1 / Phase 2 | Terminated | University of Kansas Medical Center | 1 | 2018-05-02 | 2024-07-16 |
| Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss anakinra - Hearing Loss, Sudden | Phase 1 / Phase 2 | Terminated | Andrea Vambutas | 2 | 2013-10-01 | 2017-03-13 |
| Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B SAR421869 - Usher Syndrome, Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | Sanofi | 9 | 2012-03-26 | 2022-04-28 |
| Intratympanic Injection for Autoimmune Inner Ear Disease Golimumab - Autoimmune Inner Ear Disease | Phase 1 / Phase 2 | Terminated | House Research Institute | 16 | 2012-03-01 | 2013-10-14 |
Hearing Loss, Bilateral (1) · Hearing Loss, Sensorineural (1) · Hearing Loss, Sudden (1) · Retinitis Pigmentosa (1) · Tympanic Membrane Perforation (1) · Usher Syndromes (1)
Ear Diseases (5) · Hearing Disorders (5) · Nervous System Diseases (5) · Neurologic Manifestations (5) · Otorhinolaryngologic Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Sensation Disorders (5) · Signs and Symptoms (5) · Abnormalities, Multiple (1) · Blindness (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Deaf-Blind Disorders (1) · Deafness (1)
Interleukin 1 Receptor Antagonist Protein (1) · golimumab (1)
Andrea Vambutas (1) · Frequency Therapeutics (1) · House Research Institute (1) · Sanofi (1) · University of Kansas Medical Center (1)
United States (4) · France (1)
Andrea Vambutas, MD (1) · Carl LeBel, PhD (1) · Hinrich Staecker, MD (1) · Jennifer Derebery, MD (1) · Jose-Alain Sahel, MD, PhD (1) · Richard Weleber, MD (1)